Sara C. Gavenonis, MD
is a Radiology Diagnostic Radiology specialty provider based out of Newark, Delaware. The NPI number for Sara C. Gavenonis, MD
. Based on a NPI lookup from the NPI registry (NPPES), this provider holds a license number MD431328 (Pennsylvania).
Based on Medicare data from 2014, the provider did
accept the Medicare approved amount as payment in full. She did
participate in the Physician Quality Reporting System (PQRS), which is a Medicare program that encourages healthcare professionals and group practices to report information on their respective quality of care. The provider did not
utilize electronic health records (EHR systems), which are important because they may improve a healthcare professional's ability to make well-informed treatment decisions. She did not
participate in the 'Maintenance of Certification Program' (MOC), which encourages board certified physicians to continue learning and self-evaluating throughout their medical career. The provider did not
participate in the 'Million Hearts' initiative (MHI), which is a national initiative that encourages health care professionals to report and perform well on activities related to heart health in an effort to prevent heart attacks and strokes.
Taxonomy definitions, as per the National Uniform Claim Committee (NUCC): A radiologist who utilizes x-ray, radionuclides, ultrasound and electromagnetic radiation to diagnose and treat disease.Frequently Asked Questions:
What medical school
did Sara C. Gavenonis, MD attend?
What is Sara C. Gavenonis, MD's practice location
What clinic group practices
is Sara C. Gavenonis, MD a part of?
What PubMed-indexed publications
have been authored by Sara C. Gavenonis, MD?
What are the statistics (i.e. demographics)
of Sara C. Gavenonis, MD's patients?
What medical services and procedures
does Sara C. Gavenonis, MD provide?
What durable medical equipment, prosthetics, orthotics, and supplies (DMEPOS)
did Sara C. Gavenonis, MD provide?
What drugs / medications have been prescribed
by Sara C. Gavenonis, MD?
How many open payments from the drug industry (i.e. pharmaceutical companies)
has Sara C. Gavenonis, MD received?